Second, clinicians should be aware of the ever-increasing armamentarium of therapies (such as TNF inhibitors) in chronic inflammatory disease states (such as RA or inflammatory myopathies), and that these together may pose a cumulative risk for malignancy. The gene discussed is TNF; the disease is myopathy.